Exelixis, Inc. (NASDAQ:EXEL) Stake Boosted by Nisa Investment Advisors LLC

Nisa Investment Advisors LLC boosted its stake in shares of Exelixis, Inc. (NASDAQ:EXEL) by 1,176.4% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 62,414 shares of the biotechnology company’s stock after buying an additional 57,524 shares during the period. Nisa Investment Advisors LLC’s holdings in Exelixis were worth $2,078,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. V Square Quantitative Management LLC purchased a new stake in Exelixis in the 3rd quarter worth about $30,000. USA Financial Formulas acquired a new position in shares of Exelixis in the 4th quarter valued at about $32,000. Brooklyn Investment Group purchased a new stake in shares of Exelixis in the third quarter worth approximately $42,000. UMB Bank n.a. boosted its holdings in shares of Exelixis by 68.4% during the fourth quarter. UMB Bank n.a. now owns 1,361 shares of the biotechnology company’s stock worth $45,000 after purchasing an additional 553 shares during the period. Finally, Capital Performance Advisors LLP purchased a new position in Exelixis during the third quarter valued at approximately $61,000. 85.27% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, EVP Dana Aftab sold 1,162 shares of the stock in a transaction that occurred on Wednesday, October 30th. The stock was sold at an average price of $31.40, for a total transaction of $36,486.80. Following the sale, the executive vice president now directly owns 498,945 shares in the company, valued at $15,666,873. This represents a 0.23 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Patrick J. Haley sold 41,588 shares of Exelixis stock in a transaction on Monday, November 18th. The shares were sold at an average price of $34.36, for a total value of $1,428,963.68. Following the completion of the transaction, the executive vice president now owns 288,665 shares of the company’s stock, valued at approximately $9,918,529.40. The trade was a 12.59 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 289,736 shares of company stock worth $10,139,360 in the last quarter. 2.85% of the stock is owned by corporate insiders.

Exelixis Stock Down 5.1 %

NASDAQ:EXEL opened at $32.38 on Monday. The firm has a 50-day moving average price of $34.87 and a 200 day moving average price of $29.82. The firm has a market capitalization of $9.25 billion, a PE ratio of 20.76, a price-to-earnings-growth ratio of 0.72 and a beta of 0.53. Exelixis, Inc. has a 12-month low of $20.01 and a 12-month high of $37.59.

Exelixis (NASDAQ:EXEL) last announced its quarterly earnings results on Tuesday, October 29th. The biotechnology company reported $0.40 EPS for the quarter, beating the consensus estimate of $0.36 by $0.04. Exelixis had a return on equity of 20.99% and a net margin of 22.43%. The business had revenue of $539.50 million for the quarter, compared to analyst estimates of $490.31 million. During the same quarter in the previous year, the firm earned $0.10 EPS. Exelixis’s quarterly revenue was up 14.3% on a year-over-year basis. On average, research analysts expect that Exelixis, Inc. will post 1.74 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on EXEL. Morgan Stanley lifted their target price on shares of Exelixis from $26.00 to $28.00 and gave the company an “equal weight” rating in a research note on Friday, October 11th. Stifel Nicolaus lifted their price objective on Exelixis from $26.00 to $30.00 and gave the company a “hold” rating in a research report on Wednesday, October 16th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $34.00 target price on shares of Exelixis in a research report on Wednesday, October 30th. TD Cowen boosted their price target on Exelixis from $27.00 to $34.00 and gave the company a “buy” rating in a research note on Monday, October 21st. Finally, HC Wainwright raised their price objective on shares of Exelixis from $29.00 to $40.00 and gave the company a “buy” rating in a research report on Friday, January 10th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, ten have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $35.00.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.